|Bid||4.0000 x 3000|
|Ask||4.0100 x 1100|
|Day's range||3.9150 - 4.1600|
|52-week range||0.4800 - 15.6900|
|Beta (5Y monthly)||1.80|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Leading the call today is Dr. Erik Holmlin, CEO of Bionano. Such forward-looking statements are based upon current expectations, and there can be no assurances that the results contemplated in these statements will be realized.
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -16.67% and 16.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech stocks appear to be poised for a strong showing in November for a host of reasons. Second, the latest earnings reports from top big pharma companies like Merck have been better than expected so far. Lastly, scores of drugmakers are slated to release key clinical and regulatory updates this month.